# Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

> **NCT00959192** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** ACC-001
- **OTHER:** QS-21
- **OTHER:** QS-21

## Key facts

- **NCT ID:** NCT00959192
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959192, "Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00959192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*